AzTrials
AzTrials

Dental CariesNCT07507136

Novel Dental Cements (ALBO-MPCA) in Patients With Caries

A study testing ALBO MPCA in people with Dental Caries, run by Albos d.o.o. Beograd at 1 site in Bosnia and Herzegovina.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cements on the base of the calcium silicates, like Mineral trioxide aggregate (MTA), and our cement mixture ALBO MPCA, as the object of this clinical trial, have various clinical applications. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dental Caries
What is being tested?
ALBO MPCA
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteBosnia and Herzegovina
Study dates
3 Apr 2023to 26 Feb 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed consent has been signed
  • Age 18 years and above
  • Carious teeth that had no previous treatment
  • Pulpal diagnosis of normal, healthy pulp
  • Symptomless, curiously exposed vital teeth
  • No clinical symptoms or evidence of pulp degeneration, such as history of spontaneous pain and tenderness to percussion, history of swelling or sinus tracts, pathologic mobility
Show all 9Show fewer
  • Teeth are restorable
  • No radiographic evidence of pulp degeneration, such as internal or external resorption, inter-radicular, and/or periapical bone destruction, or pulp stones
  • No clinical evidence of pulp degeneration, such as excessive bleeding from the pulp

Who cannot join

  • Pregnancy and lactation 6 months before the study and during the study
  • Significant renal or hepatic impairment
  • Subject with a life expectancy of less than 6 months
  • Subjects with unacceptable occlusal interferences oral hygiene, and non-compliant patients
  • History of irreversible pulpal pain
  • Immature teeth
Show all 12Show fewer
  • Non-restorable teeth
  • Teeth with active periodontal disease
  • History of any systemic disease
  • Concurrent medication with systemic steroids, antibiotics, analgetics, immunomodulatory drugs, or cytostatics
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
  • Participation in another research trial involving an investigational product in the past 12 weeks

Trial locations and contacts

1 site in 1 country.

Bosnia and Herzegovina1 site
  • Health House Foča

    Foca

Other trials in Bosnia and Herzegovina

About this study

Official title: The First/Second Phase of an Open Clinical Trial of Calcium-based Silicate ALBO-MPCA in Patients by Using Method of Direct or Indirect Pulp Capping

Cements on the base of the calcium silicates, like Mineral trioxide aggregate (MTA), and our cement mixture ALBO MPCA, as the object of this clinical trial, have various clinical applications. In the field of dentistry, they can be used in many ways during endodontic treatment procedures of both primary and permanent teeth. The high prevalence and recurrent nature of dental caries and periodontal disease demand endodontic treatment procedures.

According to the World Health Organization (WHO), the Global Burden of Disease Study 2017 reported that untreated dental caries in permanent teeth is the most common health condition among the population. It has also been reported that 2.3 billion adults suffer from dental caries of permanent teeth, and over 530 million children suffer from dental caries of primary teeth (milk teeth) across the globe. Thus, the growing prevalence of tooth decay and gum diseases is likely to favor the growth of the market during the next period. The overall prevalence of caries increases with age, and the incidence rises steeply in adults older than 30-40 years. Such a burden of caries will continue to increase with the growing ageing population.

Read more

The Global Burden of Disease Study in 2016 estimated that oral diseases affected half of the world's population (3.58 billion people), with dental caries in permanent teeth being the most prevalent condition assessed, while in children aged this number accounts for about 486 million. Early identification of children who are at high risk for dental caries indicates the need for a Caries-Risk Assessment (CRA) tool. Early CRA literature confirms the value of the identification of caries as a reliable way to predict future caries.

On the basis of World Health Organization (WHO) data for decayed, missing, and filled teeth (DMFT), dental decay is the most prevalent chronic disease, and it is correlated to the consumption of carbohydrates and enamel demineralization due to microorganisms. More than 90% of people suffer from this disease. WHO reported that 60% to 90% of schoolchildren all around the world suffer from dental decay, and it is more prevalent in Asian countries and Latin America.

In some reports in Bosnia and Herzegovina, almost all of the examined children had caries. The DMFT index shows that the number of diseased teeth is more than 4, even in the teenage years. In Serbia, only 8.5% of the population has all healthy teeth, while 9.3% of the population is toothless. Total income related to the caries healing is about 100 Euros per inhabitant, assuming that dental health control is regular, and if only one intervention on the teeth is made during one year. This is an enormous amount of money, showing the huge economic importance of the topic. Economical estimation for Bosnia and Hercegovina show income order of several tens of millions KM, therefore, successful treatment of caries has huge importance from the financial aspect also. In Serbia is a similar situation.

The application of the ALBO-MPCA in various endodontic indications is considered the essential method for significant improvement of oral health for patients with advanced periodontitis. Following the main requirements for an ideal dental cement, such as its fast setting, pretty high compressive strength, satisfactory chemistry, antimicrobial properties, and particularly high biocompatibility and non-toxicity ALBO-MPCA shows the significant advantages compared with recently used dental calcium silicate cements, particularly expressed in its extraordinary high depth of the reparative dentin bridge, approved in a wide scale of animal assays. Therefore, it will be applied in clinical trials, for the healing of the tooth canal, direct pulp capping, and other endodontic applications, typical for such kinds of medical devices. Financial support of the study is provided by the sponsor's consortium, with ALBOS as the sponsor. The recruitment site is the House Health, Foča in the Republic of Srpska, Bosnia and Herzegovina.

Conditions
Dental Caries
Being tested
ALBO MPCA
Medical subject headings
Dental Caries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ALBO MPCADevice

    ALBO MPCA represents the composite material, which consists of the active calcium silicate phase as a binder of this product, fillers that are constituted from calcium carbonate or/and/or hydroxyapatite, and gypsum, and a radiopaque phase consisting of barium sulphate or/and /or zirconium dioxide. The product has very good mechanical properties, extraordinary fast setting, excellent contrast, selling ability, and bioactivity. Due to its excellent biological properties, it is very promising as a material with high capacity for forming new dentine bridges with high thickness, which is crucial for clinical application in direct and indirect pulp capping.

Study groups in NCT07507136
Study groupRoleWhat they receive
ALBO MPCA groupExperimentalNot described
Receives: Device: ALBO MPCA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety evaluation during direct or indirect pulp capping and filling of the tooth roots, focusing on the tooth's pulp vitality, percussion, swelling, pain, and visual teeth changes

    Monitoring and reporting SAE and AE

    Measured: 6 months

  2. Depth of reparative dentin after medical device application, and formation of a thick dentin bridge, determined by CBCT and explained in mm

    The reparative dentin depth, considered as the difference of dentine before and after 6 months from implantation of the medical device, determined by CBCT, is considered the main measure of direct or indirect pulp capping efficiency.

    As a valuable criterion of efficiency of a medical device, the reparative dentine depth close 150 µm is chosen.

    Measured: 6 months

Secondary outcomes (4)
  1. Calcification of pulpal stone, after direct or indirect pulp capping, determined by CBCT and explained in mm

    Teeth with pulpal stone, e.g. teeth with calcified masses of mineralized tissue found within the dental pulp chamber or root canals should be divided into two group: first with teeth which contain dentine and second group which teeth do not have dentin. The presence dentine is determined by CBCT, and explained in mm.

    Measured: 6 months

  2. Pulpal volume determination, after direct or indirect pulp capping, determined by CBCT and explained in mm

    Pulpal volume determination assumes the quantifying od the three-dimensional space of the dental pulp chamber and canals, by micro-CT using software segmentation to measure pulp volume and tooth volume (PV/TV) ratios.

    Measured: 6 months

  3. Tooth pain

    Pulpal tooth pain test after 7 days and 3 months after direct and indirect pulp capping should be determined using the thermal test, by taping the teeth, to determine the vitality of the pulp (0 - no pain (healthy), 1 - pain (unhealthy)).

    Measured: 3 months

  4. Swelling or flare-up

    Swelling or flare-up 3 months after direct and indirect pulp capping, using a small, thin ruler with millimeter markings inserted gently between the teeth and gum line. Criteria of the health of gums and bone support is given by scale 1-5 mm, where 1-3 mm corresponds to healthy state, 4 mm indicate gingivitis or inflammation and 5 mm or more periodontal pockets.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2026
  2. Study start3 Apr 2023
  3. Primary completion3 Apr 2024
  4. Study completion26 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07507136
Sponsor's protocol ID
ALMBIH CT ID 08-07.5-1753-1/23
Status last verified
Mar 2026
First submitted
17 Mar 2026
Last updated
2 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing ALBO MPCA in people with Dental Caries, run by Albos d.o.o. Beograd at 1 site in Bosnia and Herzegovina.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bosnia and Herzegovina. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety evaluation during direct or indirect pulp capping and filling of the tooth roots, focusing on the tooth's pulp vitality, percussion, swelling, pain, and visual teeth changes (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in